Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab

BACKGROUND: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2. METHODS: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Thornton, Jeanine Rempe, Harel, Asaff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318946/
https://www.ncbi.nlm.nih.gov/pubmed/32622338
http://dx.doi.org/10.1016/j.msard.2020.102341
_version_ 1783550961840553984
author Thornton, Jeanine Rempe
Harel, Asaff
author_facet Thornton, Jeanine Rempe
Harel, Asaff
author_sort Thornton, Jeanine Rempe
collection PubMed
description BACKGROUND: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2. METHODS: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology. RESULTS: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection. CONCLUSIONS: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production.
format Online
Article
Text
id pubmed-7318946
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-73189462020-06-29 Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab Thornton, Jeanine Rempe Harel, Asaff Mult Scler Relat Disord Correspondence BACKGROUND: It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2. METHODS: Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology. RESULTS: A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection. CONCLUSIONS: Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production. Elsevier B.V. 2020-09 2020-06-26 /pmc/articles/PMC7318946/ /pubmed/32622338 http://dx.doi.org/10.1016/j.msard.2020.102341 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Thornton, Jeanine Rempe
Harel, Asaff
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
title Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
title_full Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
title_fullStr Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
title_full_unstemmed Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
title_short Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
title_sort negative sars-cov-2 antibody testing following covid-19 infection in two ms patients treated with ocrelizumab
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318946/
https://www.ncbi.nlm.nih.gov/pubmed/32622338
http://dx.doi.org/10.1016/j.msard.2020.102341
work_keys_str_mv AT thorntonjeaninerempe negativesarscov2antibodytestingfollowingcovid19infectionintwomspatientstreatedwithocrelizumab
AT harelasaff negativesarscov2antibodytestingfollowingcovid19infectionintwomspatientstreatedwithocrelizumab

Ejemplares similares